Dynavax Technologies | DVAX - تكلفة المبيعات



تكلفة المبيعات تغيير تاريخ
AbbVie USD 4.55B 757M 2025-12
Adma Biologics USD 50.4M 8.24M 2025-12
Agenus USD 642K 399K 2025-09
Amgen USD 1.79B 128M 2025-12
AstraZeneca USD 3.27B 471M 2025-12
Biogen USD 810.1M 205.1M 2025-09
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Glaxosmithkline GBP 3.47B 461.37M 2025-12
Merck USD 3.32B 531M 2025-12
Minerva Neurosciences 386K 31K 2024-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novartis USD 3.54B 3M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Roche Holding CHF 8.48B 4.61B 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
TG Therapeutics USD 38.14M 10.05M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12